Findings estimate the limited eligibility in typical older adults with cognitive impairment for anti-β-amyloid mAbs.
No takes yet. Share an insight, caveat, or question.
Pittock et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: